Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Helix BioPharma Corp

HBP.TO ✓ COMPLIANT ☆ Track — members

TSX · Healthcare · Biotechnology & Medical Research ·

Canada Micro Cap Analyst: N/A

Last Close

$1.35

▲ +3.89%

Market Cap $102.54M · Vol 3.23K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$102.54M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

95.92

Momentum

Beta

-0.24

vs Market

52W High

$3.89

65.20% below

52W Low

$0.79

72.88% above

Volume

3.23K

Avg 1.17K

P/B

5.09

Price-to-book

ROE

N/A

Return on equity

Free Float

58.10%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Helix BioPharma Corp (HBP.TO) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does HBP.TO pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+16.88%

+29.86%

+19.11%

+1.08%

YTD

-21.10%

+53.28%

+76.49%

-53.25%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-3,757,580.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-51.30% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	5.09
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	76.38M

Technical Indicators

50-Day SMA	$1.07
200-Day SMA	$1.35
RSI (14)	95.92
Beta	-0.24
52-Week High	$3.89
52-Week Low	$0.79

Volume Today	3.23K
Avg Daily Volume (30D)	1.17K
Relative Volume	2.76x
Volatility (10D)	33.89
Volatility (30D)	36.65
Free Float	58.10%

Analyst Consensus

N/A

Current Price $1.35

Mean Target N/A

52W Low$0.79 52W High$3.89

Current

Target

$0.79 $3.89

Current Analyst target

· 0 analysts

Identifiers

ExchangeTSX

FIGIBBG001S66SP8

ISINCA4229102088

CountryCanada

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Helix BioPharma Corp. is a clinical-stage biopharmaceutical company developing therapies in the field of immuno-oncology for the prevention and treatment of cancer based on its proprietary technological platform DOS47. The Company’s pipeline is led by Tumor Defense Breaker L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with the Company's next-generation bi-specific antibody-drug conjugates (ADCs), in discovery. The Company is also advancing two pre-IND candidates: LEUMUNA, an oral immune checkpoint modulator aimed at achieving durable remission in post-transplant leukemia relapse, and GEMCEDA, an oral gemcitabine prodrug with bioavailability on a par with IV, designed to expand treatment options for advanced cancers.